Researchers at the University of Waterloo have developed a new system that could significantly speed up the discovery of new drugs and reduce the need for costly and time-consuming laboratory tests.
The new technology called Pattern to Knowledge (P2K) can predict the binding of biosequences in seconds and potentially reduce bottlenecks in drug research.
P2K uses artificial intelligence (AI) to leverage deep knowledge from data instead of relying solely on classical machine learning.
“P2K is a game changer given its ability to reveal subtle protein associations entangled in complex physiochemical environments and powerfully predict interactions based only on sequence data,” said Andrew Wong, professor, Systems Design Engineering, and Founding Director, Centre for Pattern Analysis and Machine Intelligence (CPAMI). “The ability to access this deep knowledge from proven scientific results will shift biological research going forward. P2K has the power to transform how data could be used in the future.”
Although a large amount of biological sequence data has been collected, extracting meaningful and useful knowledge hasn’t been easy. P2K algorithms tackle this challenge by disentangling multiple associations to identify and predict amino acid bindings that govern protein interactions. Since P2K is much faster than existing biosequence analysis software with almost 30 per cent better prediction accuracy, it could significantly speed up the discovery of new drugs. By drawing information from databases in the Cloud, P2K could predict how tumour proteins and potential cancer treatments would interact.
Although still in the early prototype stage, Professor Wong and his team have made the online P2K system available publicly to researchers to start identifying new bio-sequence interactions.
“Putting this AI technology in the hands of biomedical researchers will generate immediate results, which could be used for future scientific discoveries,” said Antonio Sze-To, research associate, Systems Design Engineering, and co-inventor of P2K.
Since it analyzes sequential data, the applicability of P2K isn’t limited to biomedical research. P2K could benefit the financial industry by making useful associations and predictions for smart trading or the cybersecurity sector by predicting the likelihood of a potential cyber attack.
Learn more: New deep knowledge AI system could resolve bottlenecks in drug research
The Latest on: Drug discovery
[google_news title=”” keyword=”drug discovery” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Drug discovery
- Small Molecule Drug Discovery Market 2023 Growth Factor Details for Business Development Forecasts Up to 2030on March 28, 2023 at 8:14 pm
Mar 28, 2023 (Alliance News via COMTEX) -- Quadintel published a recovery-based report for Global Small Molecule Drug Discovery Market that provides crucial details on company opportunities, growth ...
- Global Cell Based Assays Market Report to 2028: Increasing Number of Drug Discovery Activities Will Fuel Growthon March 28, 2023 at 5:30 pm
The "Cell Based Assays Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F Segmented By Products & Services (Reagents, Assay Kits, ...
- 2023 to 2030 Drug Discovery Software Market Upcoming Trendson March 28, 2023 at 3:14 pm
The global Drug Discovery Software market size was valued at USD 2603.92 million in 2022 and is expected to expand at a CAGR of 14.76% during the forecast period, reaching USD 5948.63 million by 2028.
- Roivant’s Covant Therapeutics and BI join forces to explore covalent drug spaceon March 28, 2023 at 11:50 am
As part of the co-development deal with BI, Covant gets $10 million upfront and up to $471 million in potential milestones and tiered royalties.
- Advancing drug discovery through multitask learning techniqueson March 28, 2023 at 11:50 am
Following our recommendations, researchers in drug discovery will enhance the predictive accuracy of their models and accelerate the identification of novel drug candidates." More information: ...
- FluidForm Presents Data Demonstrating Performance of its Cardiac Drug Discovery Platformon March 28, 2023 at 11:25 am
Results demonstrate that FRESH 3D bioprinted cardiac tissues represent a novel in-vitro platform for pharmacology and toxicology screening SUDBURY, Mass., /PRNewswire-PRWeb/ --FluidForm, a leader in ...
- Tiny multiomics biotech secures former J&J drug, new execs and new financingon March 28, 2023 at 8:17 am
A new spinout from Belgium’s argenx seeks to give new life to a candidate once in-licensed to J&J. OncoVerity announced Monday afternoon that it had in-licensed cusatuzumab from argenx. The biotech ...
- Greenfield police arrest 2 men after high-speed chase and drug discoveryon March 28, 2023 at 5:12 am
A police chase in Greenfield ended in the arrest of two men early Monday morning after speeds of up to 75 mph and a successful PIT maneuver by police.Greenfield police tell CBS ...
- Mindset Pharma CEO discusses expansion of drug discovery efforts into novel non-hallucinogenic therapeuticson March 28, 2023 at 4:50 am
Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF). is expanding its drug discovery efforts into novel non-hallucinogenic therapeutics in light of the success of its psychedelic therapeutic programs, the ...
via Bing News